Patient and community preferences for treatments and health states in multiple sclerosis

被引:37
作者
Prosser, LA
Kuntz, KM
Bar-Or, A
Weinstein, MC
机构
[1] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Harvard Ctr Risk Anal, Dept Hlth Policy & Management, Boston, MA 02115 USA
[4] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
关键词
multiple sclerosis; patient preferences; quality of life; utility;
D O I
10.1191/1352458503ms903oa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To examine preferences for treatments and health states for patients with relapsing-remitting MS and members of the community. Methods: A survey was developed to evaluate health-related quality-of-life measures (utilities) for three treatments and six MS health states using a utility-elicitation software package, U-Titer II. Sixty-two MS patients at two large teaching hospitals in Boston, MA, and 67 members of the general community in San Diego, C A, completed the health-related quality-of-life survey using a computer. Results: Assessment of quality of life decreased as disability level of MS health states increased for both respondent groups. Respondents rated less-disabled health states relatively highly (>0.94 for patients and >0.89 for community respondents). Quality-of-life measures for treatments in mean utilities ranged from 0.80 to 0.96. Patients assigned higher utilities for both MS health states and treatment states than community respondents; the ratings became more disparate as health states worsened. Conclusions: On average, respondents assigned utilities to currently available treatments for MS that are comparable to those of mild to moderate stages of the disease itself. These results under score the importance of including preferences for health states and treatment alternatives in the decision to initiate treatment for individual patients or in the evaluation of effectiveness or cost-effectiveness of these treatments in patients with MS.
引用
收藏
页码:311 / 319
页数:9
相关论文
共 37 条
[1]   Are health states "timeless"? The case of the standard gamble method [J].
Bala, MV ;
Wood, LL ;
Zarkin, GA ;
Norton, EC ;
Gafni, A ;
O'Brien, BJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (11) :1047-1053
[2]  
Bennett KJ, 1996, QUALITY LIFE PHARMAC, P253
[3]   Validation of the functional assessment of multiple sclerosis quality of life instrument [J].
Cella, DF ;
Dineen, K ;
Arnason, B ;
Reder, A ;
Webster, KA ;
Karabatsos, G ;
Chang, C ;
Lloyd, S ;
Mo, F ;
Stewart, J ;
Stefoski, D .
NEUROLOGY, 1996, 47 (01) :129-139
[4]  
Comi G, 2000, NEUROLOGY, V54, pA85
[5]  
Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO
[6]  
2-N
[7]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[8]   MULTIATTRIBUTE HEALTH-STATUS CLASSIFICATION SYSTEMS - HEALTH UTILITIES INDEX [J].
FEENY, D ;
FURLONG, W ;
BOYLE, M ;
TORRANCE, GW .
PHARMACOECONOMICS, 1995, 7 (06) :490-502
[9]  
Feeny D., 1996, QUALITY LIFE PHARMAC, P239
[10]  
Gold MR, 1996, COST EFFECTIVENESS H